EESO yields 10000000.00% · ABBV yields 3.12%● Live data
📍 EESO pulled ahead of the other in Year 1
Combined, EESO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EESO + ABBV for your $10,000?
Enzyme Environmental Solutions, Inc. produces and sells industrial and agricultural enzyme products primarily in the United States. The company's enzyme products include cleaners, carpet shampoo cleaners, fabric prewash treatment, fleet and vehicle wash, glass and SS cleaners, bio gest, pit liquefiers, grease busters, industrial cleaners, laundry detergents, and mold and mildew cleaners. It also provides odor eliminators, rinse free floor cleaners, septic tank cleaners, tile and bath cleaners, toilet bowl cleaners, upholstery cleaners, vomit and odor remediation kits, and whirlpool and spa green clean systems. In addition, the company offers enzyme solutions to eliminate odor and organic matter, including blood stains; to clean carpets and counter tops; remove wall papers; and as a cleaner/degreaser. Its products are used in various industries, such as cleaning, health, and manufacturing, as well as for use as dietary supplements for humans and animals. The company was formerly known as Cucos Inc. and changed its name to Enzyme Environmental Solutions, Inc. in March 2008. Enzyme Environmental Solutions, Inc. was incorporated in 1981 and is based in Chicago, Illinois.
Full EESO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.